<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article
  PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">IJS</journal-id>
<journal-id journal-id-type="hwp">spijs</journal-id>
<journal-id journal-id-type="nlm-ta">Int J Surg Pathol</journal-id>
<journal-title>International Journal of Surgical Pathology</journal-title>
<issn pub-type="ppub">1066-8969</issn>
<issn pub-type="epub">1940-2465</issn>
<publisher>
<publisher-name>SAGE Publications</publisher-name>
<publisher-loc>Sage CA: Los Angeles, CA</publisher-loc>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.1177/1066896912438589</article-id>
<article-id pub-id-type="publisher-id">10.1177_1066896912438589</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Original Articles</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Use of Fluorescence In Situ Hybridization to Distinguish Metastatic Uveal From Cutaneous Melanoma</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name><surname>Fang</surname><given-names>Yuqiang</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912438589">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Wang</surname><given-names>Xuan</given-names></name>
<degrees>MD, PhD</degrees>
<xref ref-type="aff" rid="aff2-1066896912438589">2</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Dusza</surname><given-names>Stephen</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1066896912438589">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Jhanwar</surname><given-names>Suresh</given-names></name>
<degrees>PhD</degrees>
<xref ref-type="aff" rid="aff1-1066896912438589">1</xref>
</contrib>
<contrib contrib-type="author">
<name><surname>Abramson</surname><given-names>David</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912438589">1</xref>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name><surname>Busam</surname><given-names>Klaus J.</given-names></name>
<degrees>MD</degrees>
<xref ref-type="aff" rid="aff1-1066896912438589">1</xref>
</contrib>
</contrib-group>
<aff id="aff1-1066896912438589"><label>1</label>Memorial Sloan-Kettering Cancer Center, New York, NY, USA</aff>
<aff id="aff2-1066896912438589"><label>2</label>New York-Presbyterian Hospital-Weill Cornell, New York, NY, USA</aff>
<author-notes>
<corresp id="corresp1-1066896912438589">Klaus J. Busam, MD, Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Avenue, New York, NY 10065, USA Email: <email>busamk@mskc.org</email></corresp>
</author-notes>
<pub-date pub-type="epub-ppub">
<month>6</month>
<year>2012</year>
</pub-date>
<volume>20</volume>
<issue>3</issue>
<fpage>246</fpage>
<lpage>251</lpage>
<permissions>
<copyright-statement>© The Author(s) 2012</copyright-statement>
<copyright-year>2012</copyright-year>
<copyright-holder content-type="sage">SAGE Publications</copyright-holder>
</permissions>
<abstract>
<p>Metastatic lesions of malignant melanoma can on occasion be difficult to classify with regard to the primary site of origin. Given the lack of specificity of light microscopic features, ancillary studies are needed. In this study, the authors explored the possibility of distinguishing metastatic tumors derived from uveal primaries from those known to have originated from a cutaneous melanoma by fluorescence in situ hybridization (FISH) using probes for chromosome 3, 8q24, and 1p36. A total of 32 metastatic tumors were analyzed by FISH. Monosomy 3 was detected in 9 out of 16 (56.3%) cases of metastatic uveal melanoma but was not found in any of the 16 metastatic cutaneous melanomas (<italic>P</italic> &lt; .001). With regard to 1p36, amplifications were found in 8 out of 16 (50%) cases of metastatic cutaneous melanoma but not in any case of uveal melanoma (<italic>P</italic> &lt; .05). 1p36 was deleted in 3 cases of uveal and 1 case of cutaneous melanoma. Amplifications of 8q were found in 15 out of 16 (94%) cases of uveal melanoma metastases and in 12 out of 16 (75%) cases of cutaneous metastases. The findings suggest that FISH for monosomy 3 is a useful adjunct tool in the differential diagnosis of metastatic uveal versus cutaneous melanoma.</p>
</abstract>
<kwd-group>
<kwd>FISH</kwd>
<kwd>melanoma</kwd>
<kwd>metastasis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="section1-1066896912438589" sec-type="intro">
<title>Introduction</title>
<p>Although the skin is the most common source of melanomas (95%), the second most common site is the eye (uveal tract).<sup><xref ref-type="bibr" rid="bibr1-1066896912438589">1</xref>,<xref ref-type="bibr" rid="bibr2-1066896912438589">2</xref></sup> Both cutaneous and ocular melanomas develop in the same population group (age, skin, hair, eye color, and European origin), and both tumors can develop metastases at similar sites.<sup><xref ref-type="bibr" rid="bibr3-1066896912438589">3</xref><xref ref-type="bibr" rid="bibr4-1066896912438589"/>-<xref ref-type="bibr" rid="bibr5-1066896912438589">5</xref></sup> Unfortunately, differentiating the primary site of origin of a metastatic melanoma is difficult as the light microscopic features of metastatic tumors overlap. This is especially challenging for the interpretation of a hepatic or cutaneous metastasis as the first site of disease manifestation. Clinical clues are often used to aid in the interpretation of such metastases, but at times there is no apparent history of a prior melanoma or the patient may have a history of both prior cutaneous and ocular primaries.</p>
<p>The significance of identifying the primary origin of metastatic melanomas is beyond mere academic interest. Recent advances in the understanding of mutational heterogeneity of different melanoma variants have made available specific targeted therapy that is distinctly different from that used for patients with metastatic cutaneous and uveal melanoma. The discovery of activating mutations (V600E) in <italic>BRAF</italic> kinase in many cutaneous melanomas has led to the development of a BRAF inhibitor for the treatment of patients with advanced disease.<sup><xref ref-type="bibr" rid="bibr6-1066896912438589">6</xref><xref ref-type="bibr" rid="bibr7-1066896912438589"/><xref ref-type="bibr" rid="bibr8-1066896912438589"/><xref ref-type="bibr" rid="bibr9-1066896912438589"/>-<xref ref-type="bibr" rid="bibr10-1066896912438589">10</xref></sup> In contrast, uveal melanomas tend to harbor activating mutations in the α subunit of a G-protein of the Gq family, <italic>GNAQ</italic> or <italic>GNA11</italic>, which renders them sensitive to MEK inhibition.<sup><xref ref-type="bibr" rid="bibr11-1066896912438589">11</xref><xref ref-type="bibr" rid="bibr12-1066896912438589"/>-<xref ref-type="bibr" rid="bibr13-1066896912438589">13</xref></sup></p>
<p>With regard to a possible ancillary technique that may aid in the distinction of uveal from cutaneous metastases, a cytogenetic test would seem promising. A number of cytogenetic studies have revealed unique chromosomal abnormalities associated with either type of melanoma. Cutaneous melanomas often show losses of chromosomes 1p, 6q, 8p, 9p, and/or 10, and/or copy number increases of chromosomes 1q, 2, 6p, 7, 8q, 17q, and 20q.<sup><xref ref-type="bibr" rid="bibr14-1066896912438589">14</xref><xref ref-type="bibr" rid="bibr15-1066896912438589"/><xref ref-type="bibr" rid="bibr16-1066896912438589"/>-<xref ref-type="bibr" rid="bibr17-1066896912438589">17</xref></sup> In uveal melanoma, the most distinct aberration is the loss of a copy of the entire chromosome 3 (monosomy 3 or −3). Monosomy 3 is encountered in about half of uveal melanomas but is rarely seen in cutaneous melanoma or other cancer types.<sup><xref ref-type="bibr" rid="bibr18-1066896912438589">18</xref></sup> It has been established as the most significant (unfavorable) prognostic variable for patients with uveal melanoma.<sup><xref ref-type="bibr" rid="bibr2-1066896912438589">2</xref>,<xref ref-type="bibr" rid="bibr19-1066896912438589">19</xref></sup></p>
<p>Other known cytogenetic abnormalities of uveal melanomas, which are of potential interest in this context include aberrations of chromosomes 1 or 8. Amplifications of the c-<italic>MYC</italic> locus at 8q24 are frequently associated with monosomy 3 in uveal melanoma,<sup><xref ref-type="bibr" rid="bibr19-1066896912438589">19</xref><xref ref-type="bibr" rid="bibr20-1066896912438589"/><xref ref-type="bibr" rid="bibr21-1066896912438589"/>-<xref ref-type="bibr" rid="bibr22-1066896912438589">22</xref></sup> but c-<italic>MYC</italic> amplification has also been reported in cutaneous melanoma.<sup><xref ref-type="bibr" rid="bibr23-1066896912438589">23</xref>,<xref ref-type="bibr" rid="bibr24-1066896912438589">24</xref></sup> Loss of 1p36 plays a synergistic role with monosomy 3 in uveal melanoma prognosis; concurrent loss of 1p36 and monosomy 3 has been suggested to imply shorter survival than either change alone.<sup><xref ref-type="bibr" rid="bibr25-1066896912438589">25</xref></sup> However, rearrangements of the distal part of chromosome 1p, leading to loss or gain of 1p are not unique for uveal melanomas. They have also been reported in about 30% of cutaneous melanomas.<sup><xref ref-type="bibr" rid="bibr18-1066896912438589">18</xref></sup></p>
<p>In the current study, we explored the potential value of fluorescence in situ hybridization (FISH) in distinguishing metastatic tumors of uveal from those of cutaneous origin. We examined metastatic tumors (predominantly to the liver), using probes specific for 2 regions on chromosome 3, centromere 3 (<italic>CEP3</italic>) and <italic>BCL6</italic>, for c-<italic>MYC</italic> on chromosome 8 (8q24), and for chromosome 1p36.</p>
</sec>
<sec id="section2-1066896912438589" sec-type="materials|methods">
<title>Materials and Methods</title>
<sec id="section3-1066896912438589">
<title>Case Selection</title>
<p>The study was approved by the institutional review board. Recent cases of metastatic melanoma were searched from the archive of the Department of Pathology. Sixteen cases of metastatic uveal melanomas and an equal number of metastatic cutaneous melanomas with unequivocal clinical history and histopathologic diagnoses were analyzed.</p>
</sec>
<sec id="section4-1066896912438589">
<title>FISH Analysis on Formalin-Fixed Paraffin-Embedded Tissue</title>
<p>Five-micrometer-thick sections from formalin-fixed paraffin-embedded tissues were obtained and deparaffinized twice for 10 minutes in xyline at room temperature, followed by 5 minutes in 100% alcohol. The air-dried slides were then treated with 10 mM sodium citrate solution (pH 6.0) and heated for 15 minutes in a microwave, followed by pepsin (1% HCl, pH 1.5) digestion at 37°C for 10 to 15 minutes for antigen retrieval, and dehydrated in an ethanol gradient (70%, 90%, and 100%, each 2 minutes). In situ hybridization probes labeled with distinct fluorophore were then applied. The probes target centromere 3 (Vysis LSI <italic>CEP3</italic>-Spectrum Red, Abbott Molecular, Des Plaines, IL), <italic>BCL6</italic> on chromosome 3q27 (Vysis), <italic>MYC</italic> on chromosome 8q24, and chromosome 1p36. Sections with the probes were co-denatured for 5 minutes at 94°C and hybridized overnight at 37°C in a humidified chamber. The slides were washed in 0.4× SSC/0.3% NP-40 for 2 minutes at 77°C and 2× SSC/0.1% NP-40 for 1 minute at room temperature in the dark, counterstained with DAPI, and coverslipped. The slides were then read and imaged under the Zeiss immunofluorescence microscope equipped with Meta-Systems Isis software. The reader was blinded to the cutaneous or uveal origin of the melanoma samples. A minimum of 200 cells were counted. A tumor was classified as positive for monosomy 3 if at least 25% of the cells examined contained only a single copy of both <italic>CEP3</italic> and <italic>BCL6</italic>.</p>
</sec>
<sec id="section5-1066896912438589">
<title>Statistical Analysis</title>
<p>Descriptive statistics were used to describe the study population. Genetic alterations were cross-classified by anatomic location of the metastatic tumor. Because of sparse data in the cells of the contingency tables, Fisher’s exact test was used to assess statistical significance. Data management and analyses were performed with Stata v.10.1 (Stata Corporation, College Station, TX).</p>
</sec>
</sec>
<sec id="section6-1066896912438589" sec-type="results">
<title>Results</title>
<sec id="section7-1066896912438589">
<title>Patients and Tumors</title>
<p>Metastatic tumors from 16 patients with primary cutaneous and 16 patients with ocular melanoma were selected. All patients with ocular melanoma had previously undergone enucleation, and the diagnosis of choroidal melanoma was confirmed histopathologically. Eight of them were female, and 8 were male. Their ages at the time of diagnosis of metastatic disease ranged from 20 to 75 years, with a mean of 54 years and a median of 57 years. In all patients, the liver was the first site of metastatic uveal melanoma. Of the 16 patients with primary cutaneous melanoma, 12 were male and 4 were female. Their ages at the time of metastatic disease ranged from 39 to 74 years, with a mean of 59 years and a median of 57 years. Histopathologic prognostic features of the primary cutaneous melanomas could be fully assessed in 8 cases. Tumor thickness ranged from 1.3 to 13 mm (mean = 4.7 mm, median = 4 mm). All tumors were of either Clark level IV or Clark level V. Ulceration was present in 5 out of 8 cases. All tumors had a mitotic index ≥1 mitosis/mm<sup>2</sup>.</p>
</sec>
<sec id="section8-1066896912438589">
<title>FISH Findings</title>
<p>The metastatic tumors used for cytogenetic analysis from patients with ocular melanoma were all liver metastases. Of the metastatic cutaneous tumors, 9 were to the liver, 5 to the lymph nodes, 1 to the colon, and 1 to the skin. The cytogenetic findings are summarized in <xref ref-type="table" rid="table1-1066896912438589">Table 1</xref>. Monosomy 3 was detected in 9 out of 16 (56%) cases of metastatic uveal melanoma. An example of an ocular melanoma metastatic to liver with monosomy 3 is illustrated in <xref ref-type="fig" rid="fig1-1066896912438589">Figure 1</xref>. Monosomy 3 was not found in any case of metastatic cutaneous melanoma of this series. An example of a hepatic metastasis derived from a primary cutaneous melanoma with a normal copy number of chromosome 3 is shown in <xref ref-type="fig" rid="fig2-1066896912438589">Figure 2</xref>. Deletions of chromosome 1p were found in 3 out of 16 (19%) cases of metastatic uveal melanoma and 1 out of 16 (6%) cases of metastatic cutaneous melanoma. Amplifications of chromosome 1p were found in half of the metastases from a primary cutaneous melanoma but were not seen in a single case of metastatic uveal melanoma. Amplifications of 8q24 were detected in 15 out of 16 (94%) cases of uveal melanoma metastases. They were also found in 12 out of 16 (75%) cases of cutaneous melanoma metastases.</p>
<table-wrap id="table1-1066896912438589" position="float">
<label>Table 1.</label>
<caption>
<p>Association Between Anatomic Location Genetic Alterations</p>
</caption>
<graphic alternate-form-of="table1-1066896912438589" xlink:href="10.1177_1066896912438589-table1.tif"/>
<table>
<colgroup>
<col align="left"/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
<col align="char" char="."/>
</colgroup>
<thead>
<tr>
<th/>
<th align="center">Uveal Melanoma, n (%)</th>
<th align="center">Cutaneous Melanoma, n (%)</th>
<th align="center">Total, n (%)</th>
<th align="center"><italic>P</italic><sup><xref ref-type="table-fn" rid="table-fn1-1066896912438589">a</xref></sup></th>
</tr>
</thead>
<tbody>
<tr>
<td>Monosomy 3</td>
<td/>
<td/>
<td/>
<td>.001</td>
</tr>
<tr>
<td> Absent</td>
<td>7 (43.8)</td>
<td>16 (100.0)</td>
<td>23 (71.9)</td>
<td/>
</tr>
<tr>
<td> Present</td>
<td>9 (56.3)</td>
<td>0 (0.0)</td>
<td>9 (28.1)</td>
<td/>
</tr>
<tr>
<td> Total</td>
<td>16 (100)</td>
<td>16 (100)</td>
<td>32 (100)</td>
<td/>
</tr>
<tr>
<td>c-<italic>MYC</italic></td>
<td/>
<td/>
<td/>
<td>.333</td>
</tr>
<tr>
<td> Absent</td>
<td>1 (6.3)</td>
<td>4 (25.0)</td>
<td>5 (15.6)</td>
<td/>
</tr>
<tr>
<td> Present</td>
<td>15 (93.8)</td>
<td>12 (75.0)</td>
<td>27 (84.4)</td>
<td/>
</tr>
<tr>
<td> Total</td>
<td>16 (100)</td>
<td>16 (100)</td>
<td>32 (100)</td>
<td/>
</tr>
<tr>
<td>1p36</td>
<td/>
<td/>
<td/>
<td>.003</td>
</tr>
<tr>
<td> None</td>
<td>13 (81.3)</td>
<td>7 (43.8)</td>
<td>20 (62.5)</td>
<td/>
</tr>
<tr>
<td> Deletion</td>
<td>3 (18.8)</td>
<td>1 (6.3)</td>
<td>4 (12.5)</td>
<td/>
</tr>
<tr>
<td> Amplification</td>
<td>0 (0.0)</td>
<td>8 (50.0)</td>
<td>8 (25.0)</td>
<td/>
</tr>
<tr>
<td> Total</td>
<td>16 (100)</td>
<td>16 (100)</td>
<td>32 (100)</td>
<td/>
</tr>
</tbody>
</table>
<table-wrap-foot>
<fn id="table-fn1-1066896912438589">
<label>a</label>
<p>Based on Fisher’s exact test.</p>
</fn>
</table-wrap-foot>
</table-wrap>
<fig id="fig1-1066896912438589" position="float">
<label>Figure 1.</label>
<caption><p>Fluorescence in situ hybridization for monosomy 3. Metastatic uveal melanoma to liver: the tumor cells carry only 1 signal representing a copy of chromosome 3 (centromeric probe)</p></caption>
<graphic xlink:href="10.1177_1066896912438589-fig1.tif"/>
</fig>
<fig id="fig2-1066896912438589" position="float">
<label>Figure 2.</label>
<caption><p>Fluorescence in situ hybridization for monosomy 3. Metastatic cutaneous melanoma: the tumor cells carry 2 signals representing copies of chromosome 3 (centromeric probe)</p></caption>
<graphic xlink:href="10.1177_1066896912438589-fig2.tif"/>
</fig>
</sec>
</sec>
<sec id="section9-1066896912438589" sec-type="discussion">
<title>Discussion</title>
<p>Metastatic lesions of malignant melanoma are usually categorized based on the available clinical history of a prior cutaneous or extracutaneous primary tumor. However, this clinical classification is not always straightforward, and it can be difficult to determine the primary site of a metastatic melanoma nodule when, for example, a patient has no history of prior melanoma or has a history of both prior cutaneous and ocular melanoma. Given the lack of specificity of light microscopic features with regard to the most likely primary site, we examined the possibility of using an ancillary method, namely, FISH for chromosomal aberrations known to be characteristic of uveal melanoma.</p>
<p>Based on previously known chromosomal abnormalities associated with uveal melanoma, FISH probes for chromosome 3 (centromeric probe and <italic>BCL6</italic>), 1p36, and chromosome 8 (c-<italic>MYC</italic>)<sup><xref ref-type="bibr" rid="bibr22-1066896912438589">22</xref></sup> were chosen. Monosomy 3 was of particular interest and was felt to be most promising as a potential diagnostic marker because prior evidence has suggested that it is a chromosomal aberration fairly unique for uveal melanomas and common among uveal melanoma metastases. Our findings confirm that monosomy 3 detection by FISH is a valuable tool for distinction of metastatic uveal from cutaneous melanoma. More than half (56%) of the metastatic uveal melanomas of this series showed monosomy 3, whereas none of the metastatic cutaneous tumors did (<italic>P</italic> &lt; .001). Thus, a positive FISH test strongly supports the uveal origin of a metastatic melanoma. A negative test, on the other hand, is inconclusive.</p>
<p>In all, 7 out of 16 (43%) metastatic uveal melanomas of this series lacked monosomy 3, detectable by our FISH test. It is of interest in this regard that in about 5% to 10% of uveal melanomas, the monosomic chromosome 3 duplicates and results in an isodisomic chromosome 3 and loss of heterozygosity.<sup><xref ref-type="bibr" rid="bibr22-1066896912438589">22</xref></sup> Such tumors would not be detected by our FISH assay. Partial deletions of chromosome 3 may also escape detection. Thus, the FISH-negative metastatic tumors seen in our study may be a combination of uveal melanomas with isodisomic chromosome 3, partial deletion of chromosome 3, or no aberration of chromosome 3 at all. Although future studies are needed to further characterize cytogenetically the FISH-negative metastatic tumors seen in our study, the incidence of monosomy 3–negative metastatic uveal melanomas found in our series is similar to that reported by others.<sup><xref ref-type="bibr" rid="bibr26-1066896912438589">26</xref></sup></p>
<p>We also tested our tumors for <italic>MYC</italic> alterations. Overexpression of the <italic>MYC</italic> genes are seen in various cancer types.<sup><xref ref-type="bibr" rid="bibr27-1066896912438589">27</xref></sup> Amplification of c-<italic>MYC</italic> at chromosome 8q24 has been reported in cutaneous and uveal melanomas,<sup><xref ref-type="bibr" rid="bibr22-1066896912438589">22</xref>-<xref ref-type="bibr" rid="bibr24-1066896912438589">24</xref></sup> especially in metastatic lesions.<sup><xref ref-type="bibr" rid="bibr24-1066896912438589">24</xref></sup> This is consistent with what we observed in the current study. In all, 75% of metastatic cutaneous melanomas harbor <italic>MYC</italic> amplification. In uveal melanoma, <italic>MYC</italic> amplification is closely linked to monosomy 3. In one study, 50% of monosomy 3 uveal melanomas contained <italic>MYC</italic> amplification, and 100% of tumors with <italic>MYC</italic> amplification had monosomy 3.<sup><xref ref-type="bibr" rid="bibr24-1066896912438589">24</xref></sup> Among the 16 cases of metastatic uveal melanomas that were analyzed in this study, 15 (93.8%) had extra copies of 8q24. Given the high prevalence of this chromosomal anomaly in metastases from both uveal as well as cutaneous primaries, FISH testing for 8q24 is of no diagnostic value for determining the site of origin of a metastatic melanoma nodule.</p>
<p>In contrast to the high percentage of metastatic melanomas carrying 8q24 amplification, most metastatic uveal melanomas (82%) lacked copy number changes, using a probe for 1p36. If a change was noted, it was a deletion, which was found in 3 cases. On the other hand, 50% of metastatic cutaneous tumors had copy number increases at 1p36. Although this probe helps distinguish metastatic uveal from cutaneous (<italic>P</italic> &lt; .003), it is not as specific and sensitive as testing for monosomy 3.</p>
<p>Based on the recent discovery of unique mutations associated with uveal and cutaneous melanomas, an alternate or complementary approach to FISH analysis for determining the most likely primary site of a metastatic melanoma nodule would be mutation analysis.<sup><xref ref-type="bibr" rid="bibr13-1066896912438589">13</xref>,<xref ref-type="bibr" rid="bibr28-1066896912438589">28</xref>-<xref ref-type="bibr" rid="bibr30-1066896912438589">30</xref></sup> A positive mutation for <italic>BRAF</italic>, for example, would favor a cutaneous origin,<sup><xref ref-type="bibr" rid="bibr28-1066896912438589">28</xref>,<xref ref-type="bibr" rid="bibr29-1066896912438589">29</xref></sup> whereas a <italic>GNAQ</italic> or <italic>GNA11</italic> mutation would make a uveal origin more likely,<sup><xref ref-type="bibr" rid="bibr13-1066896912438589">13</xref>,<xref ref-type="bibr" rid="bibr30-1066896912438589">30</xref></sup> although rare cutaneous melanomas (eg, melanomas arising in association with a blue nevus) may also carry such mutations. A major advantage of the FISH assay compared with mutational analysis is its easier applicability to minimal tissue, such as from fine-needle aspiration material.<sup><xref ref-type="bibr" rid="bibr26-1066896912438589">26</xref>,<xref ref-type="bibr" rid="bibr31-1066896912438589">31</xref></sup> Furthermore, the FISH technique has been well incorporated into routine diagnostic practice in many pathology departments, whereas testing for <italic>GNAQ</italic>/<italic>11</italic> mutations is currently not widely available.</p>
<p>In conclusion, our findings suggest that testing metastatic melanomas by FISH for monosomy 3 can aid in distinction of cutaneous versus uveal origin. Indications for such a test include patients with a history of both uveal and cutaneous melanoma who develop a metastasis or patients with newly diagnosed metastatic melanoma but no known prior history of melanoma. We also envision the use of this test for the diagnostically difficult distinction of a blue nevus–like dermal melanoma metastasis in a patient with a history of uveal melanoma from a benign blue nevus, if monosomy 3 can be documented in a suspected metastatic lesion.<sup><xref ref-type="bibr" rid="bibr32-1066896912438589">32</xref>,<xref ref-type="bibr" rid="bibr33-1066896912438589">33</xref></sup> Thus, we believe that FISH for monosomy 3 is a valuable ancillary test for cancer centers to improve diagnostic accuracy for patients with metastatic uveal melanoma.</p>
</sec>
</body>
<back>
<fn-group>
<fn fn-type="other">
<p>Both Drs Fang and Wang made equal contributions as first authors.</p>
</fn>
<fn fn-type="conflict">
<p>The author(s) declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.</p>
</fn>
<fn fn-type="financial-disclosure">
<p>The author(s) received no financial support for the research, authorship, and/or publication of this article.</p>
</fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="bibr1-1066896912438589">
<label>1.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hussein</surname><given-names>MR</given-names></name>
</person-group>. <article-title>Extracutaneous malignant melanomas</article-title>. <source>Cancer Invest</source>. <year>2008</year>;<volume>26</volume>:<fpage>516</fpage>-<lpage>534</lpage>.</citation>
</ref>
<ref id="bibr2-1066896912438589">
<label>2.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>AD</given-names></name>
<name><surname>Bergman</surname><given-names>L</given-names></name>
<name><surname>Seregard</surname><given-names>S</given-names></name>
</person-group>. <article-title>Uveal melanoma: epidemiologic aspects</article-title>. <source>Ophthalmol Clin North Am</source>. <year>2005</year>;<volume>18</volume>:<fpage>75</fpage>-<lpage>84</lpage>.</citation>
</ref>
<ref id="bibr3-1066896912438589">
<label>3.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rietschel</surname><given-names>P</given-names></name>
<name><surname>Panageas</surname><given-names>KS</given-names></name>
<name><surname>Hanlon</surname><given-names>C</given-names></name>
<name><surname>Patel</surname><given-names>A</given-names></name>
<name><surname>Abramson</surname><given-names>DH</given-names></name>
<name><surname>Chapman</surname><given-names>PB</given-names></name>
</person-group>. <article-title>Variates of survival in metastatic uveal melanoma</article-title>. <source>J Clin Oncol</source>. <year>2005</year>;<volume>23</volume>:<fpage>8076</fpage>-<lpage>8080</lpage>.</citation>
</ref>
<ref id="bibr4-1066896912438589">
<label>4.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rose</surname><given-names>DM</given-names></name>
<name><surname>Essner</surname><given-names>R</given-names></name>
<name><surname>Hughes</surname><given-names>TM</given-names></name>
<etal/>
</person-group>. <article-title>Surgical resection for metastatic melanoma to the liver: the John Wayne Cancer Institute and Sydney Melanoma Unit experience</article-title>. <source>Arch Surg</source>. <year>2001</year>;<volume>136</volume>:<fpage>950</fpage>-<lpage>955</lpage>.</citation>
</ref>
<ref id="bibr5-1066896912438589">
<label>5.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Shildkrot</surname><given-names>Y</given-names></name>
<name><surname>Wilson</surname><given-names>MW</given-names></name>
</person-group>. <article-title>Update on posterior uveal melanoma: treatment of the eye and emerging strategies in the prognosis and treatment of metastatic disease</article-title>. <source>Curr Opin Ophthalmol</source>. <year>2009</year>;<volume>20</volume>:<fpage>504</fpage>-<lpage>510</lpage>.</citation>
</ref>
<ref id="bibr6-1066896912438589">
<label>6.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Flaherty</surname><given-names>KT</given-names></name>
<name><surname>Hodi</surname><given-names>FS</given-names></name>
<name><surname>Bastian</surname><given-names>BC</given-names></name>
</person-group>. <article-title>Mutation-driven drug development in melanoma</article-title>. <source>Curr Opin Oncol</source>. <year>2010</year>;<volume>22</volume>: <fpage>178</fpage>-<lpage>183</lpage>.</citation>
</ref>
<ref id="bibr7-1066896912438589">
<label>7.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Vultur</surname><given-names>A</given-names></name>
<name><surname>Villanueva</surname><given-names>J</given-names></name>
<name><surname>Herlyn</surname><given-names>M</given-names></name>
</person-group>. <article-title>Targeting BRAF in advanced melanoma: a first step toward manageable disease</article-title>. <source>Clin Cancer Res</source>. <year>2011</year>;<volume>17</volume>:<fpage>1658</fpage>-<lpage>1663</lpage>.</citation>
</ref>
<ref id="bibr8-1066896912438589">
<label>8.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wan</surname><given-names>PT</given-names></name>
<name><surname>Garnett</surname><given-names>MJ</given-names></name>
<name><surname>Roe</surname><given-names>SM</given-names></name>
<etal/>
</person-group>. <article-title>Mechanism of activation of the RAF-ERK signaling pathway by oncogenic mutations of B-RAF</article-title>. <source>Cell</source>. <year>2004</year>;<volume>116</volume>:<fpage>855</fpage>-<lpage>867</lpage>.</citation>
</ref>
<ref id="bibr9-1066896912438589">
<label>9.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Chapman</surname><given-names>PB</given-names></name>
<name><surname>Hauschild</surname><given-names>A</given-names></name>
<name><surname>Robert</surname><given-names>C</given-names></name>
<etal/>
</person-group>. <article-title>Improved survival with vemurafenib in melanoma with BRAF V600E mutation</article-title>. <source>N Engl J Med</source>. <year>2011</year>;<volume>364</volume>:<fpage>2507</fpage>-<lpage>2516</lpage>.</citation>
</ref>
<ref id="bibr10-1066896912438589">
<label>10.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Luke</surname><given-names>JJ</given-names></name>
<name><surname>Hodi</surname><given-names>FS</given-names></name>
</person-group>. <article-title>Vemurafenib and BRAF inhibition: a new class of treatment for metastatic melanoma</article-title>. <source>Clin Cancer Res</source>. <year>2012</year>;<volume>18</volume>:<fpage>9</fpage>-<lpage>14</lpage>.</citation>
</ref>
<ref id="bibr11-1066896912438589">
<label>11.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kimple</surname><given-names>AJ</given-names></name>
<name><surname>Bosch</surname><given-names>DE</given-names></name>
<name><surname>Giguère</surname><given-names>PM</given-names></name>
<name><surname>Siderovski</surname><given-names>DP</given-names></name>
</person-group>. <article-title>Regulators of G-protein signaling and their Galpha substrates: promises and challenges in their use as drug discovery targets</article-title>. <source>Pharmacol Rev</source>. <year>2011</year>;<volume>63</volume>:<fpage>728</fpage>-<lpage>749</lpage>.</citation>
</ref>
<ref id="bibr12-1066896912438589">
<label>12.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Patel</surname><given-names>M</given-names></name>
<name><surname>Smyth</surname><given-names>E</given-names></name>
<name><surname>Chapman</surname><given-names>PB</given-names></name>
<etal/>
</person-group>. <article-title>Therapeutic implications of the emerging molecular biology of uveal melanoma</article-title>. <source>Clin Cancer Res</source>. <year>2011</year>;<volume>17</volume>:<fpage>2087</fpage>-<lpage>2100</lpage>.</citation>
</ref>
<ref id="bibr13-1066896912438589">
<label>13.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Raamsdonk</surname><given-names>CD</given-names></name>
<name><surname>Bezrookove</surname><given-names>V</given-names></name>
<name><surname>Green</surname><given-names>G</given-names></name>
<etal/>
</person-group>. <article-title>Frequent somatic mutations of GNAQ in uveal melanoma and blue naevi</article-title>. <source>Nature</source>. <year>2009</year>;<volume>457</volume>:<fpage>599</fpage>-<lpage>602</lpage>.</citation>
</ref>
<ref id="bibr14-1066896912438589">
<label>14.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Balaban</surname><given-names>G</given-names></name>
<name><surname>Herlyn</surname><given-names>M</given-names></name>
<name><surname>Guerry</surname><given-names>D</given-names><suffix>4th</suffix></name>
<etal/>
</person-group>. <article-title>Cytogenetics of human malignant melanoma and premalignant lesions</article-title>. <source>Cancer Genet Cytogenet</source>. <year>1984</year>;<volume>11</volume>:<fpage>429</fpage>-<lpage>439</lpage>.</citation>
</ref>
<ref id="bibr15-1066896912438589">
<label>15.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bastian</surname><given-names>BC</given-names></name>
<name><surname>LeBoit</surname><given-names>PE</given-names></name>
<name><surname>Hamm</surname><given-names>H</given-names></name>
<name><surname>Brocker</surname><given-names>EB</given-names></name>
<name><surname>Pinkel</surname><given-names>D</given-names></name>
</person-group>. <article-title>Chromosomal gains and losses in primary cutaneous melanomas detected by comparative genomic hybridization</article-title>. <source>Cancer Res</source>. <year>1998</year>;<volume>58</volume>:<fpage>2170</fpage>-<lpage>2175</lpage>.</citation>
</ref>
<ref id="bibr16-1066896912438589">
<label>16.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Curtin</surname><given-names>JA</given-names></name>
<name><surname>Fridlyand</surname><given-names>J</given-names></name>
<name><surname>Kageshita</surname><given-names>T</given-names></name>
<etal/>
</person-group>. <article-title>Distinct sets of genetic alterations in melanoma</article-title>. <source>N Engl J Med</source>. <year>2005</year>;<volume>353</volume>:<fpage>2135</fpage>-<lpage>2147</lpage>.</citation>
</ref>
<ref id="bibr17-1066896912438589">
<label>17.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Limon</surname><given-names>J</given-names></name>
<name><surname>Dal Cin</surname><given-names>P</given-names></name>
<name><surname>Sait</surname><given-names>SN</given-names></name>
<name><surname>Karakousis</surname><given-names>C</given-names></name>
<name><surname>Sandberg</surname><given-names>AA</given-names></name>
</person-group>. <article-title>Chromosome changes in metastatic human melanoma</article-title>. <source>Cancer Genet Cytogenet</source>. <year>1988</year>;<volume>30</volume>:<fpage>201</fpage>-<lpage>211</lpage>.</citation>
</ref>
<ref id="bibr18-1066896912438589">
<label>18.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Hoglund</surname><given-names>M</given-names></name>
<name><surname>Gisselsson</surname><given-names>D</given-names></name>
<name><surname>Hansen</surname><given-names>GB</given-names></name>
<etal/>
</person-group>. <article-title>Dissecting karyotypic patterns in malignant melanomas: temporal clustering of losses and gains in melanoma karyotypic evolution</article-title>. <source>Int J Cancer</source>. <year>2004</year>;<volume>108</volume>:<fpage>57</fpage>-<lpage>65</lpage>.</citation>
</ref>
<ref id="bibr19-1066896912438589">
<label>19.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Prescher</surname><given-names>G</given-names></name>
<name><surname>Bornfeld</surname><given-names>N</given-names></name>
<name><surname>Becher</surname><given-names>R</given-names></name>
</person-group>. <article-title>Nonrandom chromosomal abnormalities in primary uveal melanoma</article-title>. <source>J Natl Cancer Inst</source>. <year>1990</year>;<volume>82</volume>:<fpage>1765</fpage>-<lpage>1769</lpage>.</citation>
</ref>
<ref id="bibr20-1066896912438589">
<label>20.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Horsman</surname><given-names>DE</given-names></name>
<name><surname>Sroka</surname><given-names>H</given-names></name>
<name><surname>Rootman</surname><given-names>J</given-names></name>
<name><surname>White</surname><given-names>VA</given-names></name>
</person-group>. <article-title>Monosomy 3 and isochromosome 8q in a uveal melanoma</article-title>. <source>Cancer Genet Cytogenet</source>. <year>1990</year>;<volume>45</volume>:<fpage>249</fpage>-<lpage>253</lpage>.</citation>
</ref>
<ref id="bibr21-1066896912438589">
<label>21.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Sisley</surname><given-names>K</given-names></name>
<name><surname>Rennie</surname><given-names>IG</given-names></name>
<name><surname>Cottam</surname><given-names>DW</given-names></name>
<name><surname>Potter</surname><given-names>AM</given-names></name>
<name><surname>Potter</surname><given-names>CW</given-names></name>
<name><surname>Rees</surname><given-names>RC</given-names></name>
</person-group>. <article-title>Cytogenetic findings in six posterior uveal melanomas: involvement of chromosomes 3, 6, and 8</article-title>. <source>Genes Chromosomes Cancer</source>. <year>1990</year>;<volume>2</volume>:<fpage>205</fpage>-<lpage>209</lpage>.</citation>
</ref>
<ref id="bibr22-1066896912438589">
<label>22.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>van den Bosch</surname><given-names>T</given-names></name>
<name><surname>Kilic</surname><given-names>E</given-names></name>
<name><surname>Paridaens</surname><given-names>D</given-names></name>
<name><surname>de Klein</surname><given-names>A</given-names></name>
</person-group>. <article-title>Genetics of uveal melanoma and cutaneous melanoma: two of a kind?</article-title> <source>Dermatol Res Pract</source>. <year>2010</year>;<volume>2010</volume>:<fpage>360136</fpage>.</citation>
</ref>
<ref id="bibr23-1066896912438589">
<label>23.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kraehn</surname><given-names>GM</given-names></name>
<name><surname>Utikal</surname><given-names>J</given-names></name>
<name><surname>Udart</surname><given-names>M</given-names></name>
<etal/>
</person-group>. <article-title>Extra c-myc oncogene copies in high risk cutaneous malignant melanoma and melanoma metastases</article-title>. <source>Br J Cancer</source>. <year>2001</year>;<volume>84</volume>:<fpage>72</fpage>-<lpage>79</lpage>.</citation>
</ref>
<ref id="bibr24-1066896912438589">
<label>24.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Parrella</surname><given-names>P</given-names></name>
<name><surname>Caballero</surname><given-names>OL</given-names></name>
<name><surname>Sidransky</surname><given-names>D</given-names></name>
<name><surname>Merbs</surname><given-names>SL</given-names></name>
</person-group>. <article-title>Detection of c-myc amplification in uveal melanoma by fluorescent in situ hybridization</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2001</year>;<volume>42</volume>:<fpage>1679</fpage>-<lpage>1684</lpage>.</citation>
</ref>
<ref id="bibr25-1066896912438589">
<label>25.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Kilic</surname><given-names>E</given-names></name>
<name><surname>Naus</surname><given-names>NC</given-names></name>
<name><surname>van Gils</surname><given-names>W</given-names></name>
<etal/>
</person-group>. <article-title>Concurrent loss of chromosome arm 1p and chromosome 3 predicts a decreased disease-free survival in uveal melanoma patients</article-title>. <source>Invest Ophthalmol Vis Sci</source>. <year>2005</year>;<volume>46</volume>:<fpage>2253</fpage>-<lpage>2257</lpage>.</citation>
</ref>
<ref id="bibr26-1066896912438589">
<label>26.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Singh</surname><given-names>AD</given-names></name>
<name><surname>Tubbs</surname><given-names>R</given-names></name>
<name><surname>Biscotti</surname><given-names>C</given-names></name>
<name><surname>Schoenfield</surname><given-names>L</given-names></name>
<name><surname>Trizzoi</surname><given-names>P</given-names></name>
</person-group>. <article-title>Chromosomal 3 and 8 status within hepatic metastasis of uveal melanoma</article-title>. <source>Arch Pathol Lab Med</source>. <year>2009</year>;<volume>133</volume>:<fpage>1223</fpage>-<lpage>1227</lpage>.</citation>
</ref>
<ref id="bibr27-1066896912438589">
<label>27.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Albihn</surname><given-names>A</given-names></name>
<name><surname>Johnsen</surname><given-names>JI</given-names></name>
<name><surname>Henriksson</surname><given-names>MA</given-names></name>
</person-group>. <article-title>MYC in oncogenesis and as a target for cancer therapies</article-title>. <source>Adv Cancer Res</source>. <year>2010</year>;<volume>107</volume>:<fpage>163</fpage>-<lpage>224</lpage>.</citation>
</ref>
<ref id="bibr28-1066896912438589">
<label>28.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Lee</surname><given-names>JH</given-names></name>
<name><surname>Choi</surname><given-names>JW</given-names></name>
<name><surname>Kim</surname><given-names>YS</given-names></name>
</person-group>. <article-title>Frequencies of BRAF and NRAS mutations are different in histological types and sites of origin of cutaneous melanoma: a meta-analysis</article-title>. <source>Br J Dermatol</source>. <year>2011</year>;<volume>164</volume>:<fpage>776</fpage>-<lpage>784</lpage>.</citation>
</ref>
<ref id="bibr29-1066896912438589">
<label>29.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Rimoldi</surname><given-names>D</given-names></name>
<name><surname>Salvi</surname><given-names>S</given-names></name>
<name><surname>Lienard</surname><given-names>D</given-names></name>
<etal/>
</person-group>. <article-title>Lack of BRAF mutations in uveal melanoma</article-title>. <source>Cancer Res</source>. <year>2003</year>;<volume>63</volume>:<fpage>5712</fpage>-<lpage>5715</lpage>.</citation>
</ref>
<ref id="bibr30-1066896912438589">
<label>30.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Van Raamsdonk</surname><given-names>CD</given-names></name>
<name><surname>Griewank</surname><given-names>KG</given-names></name>
<name><surname>Crosby</surname><given-names>MB</given-names></name>
<etal/>
</person-group>. <article-title>Mutations in GNA11 in uveal melanoma</article-title>. <source>N Engl J Med</source>. <year>2010</year>;<volume>363</volume>:<fpage>2191</fpage>-<lpage>2199</lpage>.</citation>
</ref>
<ref id="bibr31-1066896912438589">
<label>31.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Bonaldi</surname><given-names>L</given-names></name>
<name><surname>Midena</surname><given-names>E</given-names></name>
<name><surname>Filippi</surname><given-names>B</given-names></name>
<etal/>
</person-group>. <article-title>FISH analysis of chromosomes 3 and 6 on fine needle aspiration biopsy samples identifies distinct subgroups of uveal melanomas</article-title>. <source>J Cancer Res Clin Oncol</source>. <year>2008</year>;<volume>134</volume>:<fpage>1123</fpage>-<lpage>1127</lpage>.</citation>
</ref>
<ref id="bibr32-1066896912438589">
<label>32.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Busam</surname><given-names>KJ</given-names></name>
</person-group>. <article-title>Metastatic melanoma to the skin simulating blue nevus</article-title>. <source>Am J Surg Pathol</source>. <year>1999</year>;<volume>23</volume>:<fpage>276</fpage>-<lpage>282</lpage>.</citation>
</ref>
<ref id="bibr33-1066896912438589">
<label>33.</label>
<citation citation-type="journal">
<person-group person-group-type="author">
<name><surname>Wieselthier</surname><given-names>JS</given-names></name>
<name><surname>White</surname><given-names>WL</given-names></name>
</person-group>. <article-title>Cutaneous metastasis of ocular malignant melanoma. An unusual presentation simulating blue nevi</article-title>. <source>Am J Dermatopathol</source>. <year>1996</year>;<volume>18</volume>:<fpage>289</fpage>-<lpage>295</lpage>.</citation>
</ref>
</ref-list>
</back>
</article>